← board
PAHC
distress 0/10 · well-funded / low risk$33.96+0%today-43% from 52w high
Revenue
$1121M
Liquidity
$77M
Runway
—
Shares 1y
—
Price & events
-17.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
-1.6%
1W
+11.2%
1M
-37.6%
3M
-12.4%
6M
+15.4%
1Y
+85.6%
2Y
+58.5%
5Y
+97.4%
All
Overview
- Volume
- 7.78K
- 52 Week Range
- $26.11 – $59.58
- Float Shares
- 20.87M
- Short %
- 6.87%
- % Held by Insiders
- 0.85%
- % Held by Institutions
- 101.07%
- RVOL
- 0.03x
- Beta
- 0.46
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-08-26earningsEarningsEarnings releaseyahoo
- 2026-04-27withdrawalvirginiamycin and bacitracin · Brazil MAPA prohibited use of virginiamycin and bacitracin as performance enhancing feed additives, effective after 180-day transition periodSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-14CitigroupNeutral
- 2026-04-15CitigroupNeutral
- 2025-11-07JP MorganOverweight
- 2025-08-29B of A SecuritiesUnderperform
- 2025-07-07JP MorganNeutral → Overweight
- 2025-06-25Morgan StanleyEqual-Weight
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.